Immunology & Cell Biology最新文献

Cytosolic delivery of bacterial metabolites by riboflavin transporters promotes MR1 antigen presentation and MAIT cell recognition. 核黄素转运体在细胞质内递送细菌代谢物可促进MR1抗原呈递和MAIT细胞识别。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-06 DOI: 10.1111/imcb.70130

Sebastian Cruz-Gomez, Hui Jing Lim, Brunda Nijagal, Yuting Yang, Nicole Lau, Jeffrey Yw Mak, David P Fairlie, Hayley Newton, Mariolina Salio, Jose A Villadangos, Hamish Eg McWilliam

{"title":"Cytosolic delivery of bacterial metabolites by riboflavin transporters promotes MR1 antigen presentation and MAIT cell recognition.","authors":"Sebastian Cruz-Gomez, Hui Jing Lim, Brunda Nijagal, Yuting Yang, Nicole Lau, Jeffrey Yw Mak, David P Fairlie, Hayley Newton, Mariolina Salio, Jose A Villadangos, Hamish Eg McWilliam","doi":"10.1111/imcb.70130","DOIUrl":"https://doi.org/10.1111/imcb.70130","url":null,"abstract":"Major histocompatibility complex class I-related protein 1 (MR1) presents microbial Vitamin B-related metabolite antigens (VitBAg) at the cell surface to activate mucosal-associated invariant T (MAIT) cells. Precisely how antigen-presenting cells capture these MR1 ligands is not known. Here, we show that the most effective route for presentation of bacterial VitBAg involves passage through the cytosol. Consistent with structural similarities with riboflavin, we find that VitBAg presentation is inhibited by riboflavin. We further show that riboflavin carriers transport VitBAg into cells and enhance MR1 antigen presentation to MAIT cells. However, elimination of specific riboflavin carriers does not ablate VitBAg presentation, indicating cells possess redundant mechanisms to internalize this family of MR1 ligands. Our findings provide new insights into the intracellular pathway used by VitBAg to bind MR1 molecules and identify potential approaches to boost MR1-mediated MAIT cell responses for therapeutic benefits.","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147831381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The EBV-autoimmunity axis: mechanistic insights in SLE, MS and PSC. ebv -自身免疫轴：SLE， MS和PSC的机制见解。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-05 DOI: 10.1111/imcb.70127

Seyhan Yazar, Nicholas Schwab, Nicholas S R Sanderson, Jennifer Massey

引用次数: 0

Highlights of 2025: epithelial-immune circuitry in allergic airway inflammation. 2025年的亮点：过敏性气道炎症的上皮免疫回路。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-04 DOI: 10.1111/imcb.70126

Rebecca Palmer, Olivier Lamiable, Kerry L Hilligan

引用次数: 0

Highlights of 2025: the B-side of LEF1. 2025年的亮点：LEF1的b面。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-03 DOI: 10.1111/imcb.70129

Isabella Naylor, Adrian Y S Lee, Joanne Reed, Qian Shen

引用次数: 0

Gamma-irradiated Newcastle disease virus: an alternative inactivated oncolytic virotherapy. γ辐照新城疫病毒：一种替代灭活溶瘤病毒疗法。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-01 Epub Date: 2026-04-05 DOI: 10.1111/imcb.70107

Eve V Kennedy, Yimin Chuah, Amal H Mostafa, Chloe J Gates, Jade Foeng, Todd S Norton, Shaun R McColl, Iain Comerford, Justin B Davies, Farhid Hemmatzadeh, Mohammed Alsharifi

{"title":"Gamma-irradiated Newcastle disease virus: an alternative inactivated oncolytic virotherapy.","authors":"Eve V Kennedy, Yimin Chuah, Amal H Mostafa, Chloe J Gates, Jade Foeng, Todd S Norton, Shaun R McColl, Iain Comerford, Justin B Davies, Farhid Hemmatzadeh, Mohammed Alsharifi","doi":"10.1111/imcb.70107","DOIUrl":"10.1111/imcb.70107","url":null,"abstract":"Newcastle disease virus (NDV) has been investigated as an oncolytic virus in many clinical trials, demonstrating the ability of NDV to treat a range of different cancers. However, research with NDV is hindered by biosecurity risks associated with live NDV. In addition, NDV is an important poultry pathogen that is associated with widespread livestock losses and a large economic burden. While live and chemically inactivated NDV vaccines are available, they have limited efficacy and there is a need for alternative vaccines. In this study, we inactivated NDV using γ-irradiation and tested the structural integrity, immunogenicity, and oncolytic activity of γ-NDV using in vitro and in vivo models. Our data illustrate that the overall virion structure and protein function of γ-NDV are well maintained. However, we did not detect neutralizing antibody responses after intramuscular or subcutaneous γ-NDV administration in mice. While these data do not directly support the use of γ-NDV as a vaccine candidate, our data show that γ-NDV retained its ability to kill a range of different cancer cells in vitro, suggesting γ-NDV may be a potential cancer therapeutic agent. To test this, γ-NDV was trialed as an oncolytic therapy in a murine melanoma model. This revealed that γ-NDV administration outperformed live NDV in terms of reduced tumor growth and overall survival. While further investigation is required to address the suitability of γ-NDV as a poultry vaccine, our data indicate that γ-irradiation may be a suitable inactivation method for the development of a highly effective inactivated oncolytic virotherapy.","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":" ","pages":"473-484"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147621276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Scratching the surface" of cutaneous immunity where the microbiome sets the tone and itch turns the volume up. 在皮肤免疫系统的“表面抓挠”中，微生物组设定了基调，瘙痒会增加音量。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-01 Epub Date: 2026-04-23 DOI: 10.1111/imcb.70118

Aidi Han, Céline Pattaroni

引用次数: 0

One cell, many fates: transcriptional networks governing CD8⁺ T cell differentiation. 一个细胞，多种命运：控制CD8+ T细胞分化的转录网络。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-01 Epub Date: 2026-03-24 DOI: 10.1111/imcb.70106

M Zeeshan Chaudhry, Gabrielle T Belz

引用次数: 0

Highlights of 2025: plasma cell biology. 2025年的亮点：浆细胞生物学。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-01 Epub Date: 2026-04-19 DOI: 10.1111/imcb.70124

Alexandra Bosak Karaviotis, Marcus James Robinson

引用次数: 0

Gain-of-function enhancers optimize CAR-NK cell-based anti-cancer immunotherapy. 功能增强子优化CAR-NK细胞抗癌免疫治疗。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-01 Epub Date: 2026-04-10 DOI: 10.1111/imcb.70113

Emma Wong, Fernando Souza-Fonseca-Guimaraes

引用次数: 0

Defining the tumor microenvironment of non-small cell lung cancer. 定义非小细胞肺癌的肿瘤微环境。

IF 3 4区医学

Immunology & Cell Biology Pub Date : 2026-05-01 Epub Date: 2026-04-10 DOI: 10.1111/imcb.70114

Kidane Siele Embaye, Tony Blick, Vahid Yaghoubi Naei, Ken O'Byrne, Brett G M Hughes, Arutha Kulasinghe

{"title":"Defining the tumor microenvironment of non-small cell lung cancer.","authors":"Kidane Siele Embaye, Tony Blick, Vahid Yaghoubi Naei, Ken O'Byrne, Brett G M Hughes, Arutha Kulasinghe","doi":"10.1111/imcb.70114","DOIUrl":"10.1111/imcb.70114","url":null,"abstract":"Lung cancer is the most frequent cause of cancer-related mortality globally. In recent years, the treatment landscape for advanced-stage non-small-cell lung cancer (NSCLC) has been transformed by the advent of immunotherapy, which has yielded unprecedented and durable clinical responses for some patients. This shift has powered a significant expansion of novel immunotherapeutic strategies in oncology over the past few decades, heralding a new direction in the management of NSCLC. Despite these advances, only a fraction of patients acquire sustained benefit from immunotherapy, while the majority often develop resistance, resulting in disease progression leading to death. Several factors may contribute to this limited success, notably tumor heterogeneity and the intricate composition of the tumor microenvironment (TME). As a result, it is imperative to fully dissect the heterogeneity of the TME by identifying the principal drivers of cancer progression and immunotherapy resistance. This understanding is crucial for optimizing individualized treatment approaches. Here, we provide a summary of NSCLC, discuss the cardinal features of the TME and review advanced technologies such as spatial profiling of tissues, which are useful in dissecting the dynamicity of the tumor ecosystem. In addition, we highlight the recent developments and future perspectives of immunotherapy and other emerging therapeutics, as well as the role of predictive biomarker testing to ensure tailored therapy and tackle drug resistance, on the pathway to precision medicine.","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":" ","pages":"499-518"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0